AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$APGE

McKenna Mark C. sold (to issuer) 20,000 shares of APGE

McKenna Mark C. sold (to issuer) 20,000 shares of Apogee Therapeutics, Inc. (APGE) on 2026-09-03.

Original reporting
SEC EDGAR · McKenna Mark C.
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$APGE
Bearish
medium confidence
Mentioned
$APGE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APGEBearishLow
01

Why it matters

The director's complete exit may be noted by investors but is unlikely to move the stock.

02

Market read

Small insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or personal liquidity needs.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 4 filing discloses insider transactions to the SEC.

Company-level read

Ticker impact

$APGEBearishMedium confidence
Context

Director Mark C. McKenna sold 20,000 shares, leaving a zero holding.

Expected impact

Minor downward pressure, likely negligible on price.

Evidence & confidence

Small transaction size and lack of disclosed price limit market impact.

Market effects

Sector

No material effect on the biotech sector.

Regional

Limited to US investors tracking insider activity.

Global

None.

Counterpoint

What could challenge this read

The sale may be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Apogee Therapeutics, Inc.

    Biopharma company listed on NASDAQ.

  • Individual
    Mark C. McKenna

    Director of Apogee Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

APGE insider trading history →

Related articles

SEP 9
$ABBVHighAI 9/10

Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

AbbVie (ABBV) completed its $10.9B acquisition of Apogee Therapeutics (APGE) at $135.11 per share. AbbVie also reported positive Phase 3 trial results for etentamig. Q2 2026 revenue for AbbVie rose 10.2% to $16.99B, with adjusted EPS up 22.9% to $3.65. Apogee reported a net loss of $85.9M in Q2 2026. Hedge funds increased stakes in both companies ahead of the deal.

insidermonkey.com3 min
SEP 3
$ABBVHighAI 9/10

AbbVie Completes $10.9 Bln Acquisition Of Apogee Therapeutics

AbbVie (ABBV) completed its $10.9 billion acquisition of Apogee Therapeutics (APGE), paying $135.11 per share. The deal strengthens AbbVie's immunology pipeline, including Apogee's lead asset, zumilokibart, for atopic dermatitis. AbbVie expects the acquisition to be dilutive to earnings until 2032. AbbVie reaffirmed its 2026 EPS guidance of $13.87-$14.07, including a $0.14 per-share dilutive impact. ABBV closed at $261.72, up 0.67%.

rttnews.com2 min
SEP 2
$MMEDMed

Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE

Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.

rttnews.com2 min